Representation Matters in Clinical Trials

Rhea-AI Summary

Boston Scientific emphasizes the importance of diversity in clinical trials to enhance patient outcomes. In a joint effort with Medtronic, the companies aim to increase representation among trial participants to reflect the diverse populations they serve. Laura Mauri, MD, from Medtronic, highlighted that inclusive representation is essential not only for addressing health inequities but also for understanding product efficacy across varied demographics. This strategic focus on diverse clinical trials aims to improve treatment effectiveness and outcomes for a broader patient base.

Positive

• Increased representation in clinical trials aims to enhance device efficacy for diverse populations.
• Collaboration with Medtronic highlights Boston Scientific's commitment to equity in healthcare.

Negative

• None.

NORTHAMPTON, MA / ACCESSWIRE / March 1, 2023 / Boston Scientific

Originally published by Medical Device + Diagnostic Industry

Clinical trials are an early step in device and therapy development which have significant impact on the types of products available to patients. The demographics of patients in these trials carries an impact on products, making diversity in clinical trials key to ensure all patient needs are being evaluated, and targeted for treatments. Medtronic and Boston Scientific share the efforts the companies have undertaken to broaden the patients in their clinical trials.

"We cannot provide the best therapies across the world unless we fully represent the range of people who are affected," said Laura Mauri, MD, senior vice president, chief scientific, medical, and regulatory officer at Medtronic. "Diverse representation in our research and development is not only a social imperative that is needed to interrupt the cycle of health inequity, but also a clinical necessity to fully understand our products. Diversity allows us to better reflect the entirety of the population we're trying to serve, improve device efficacy across that entire population, and ultimately improve outcomes for a broader group of patients and communities."

Continue reading here.

Image credit: Ariel Skelley / The Image Bank via Getty Images

View additional multimedia and more ESG storytelling from Boston Scientific on 3blmedia.com.

Contact Info:
Spokesperson: Boston Scientific
Website: https://www.3blmedia.com/profiles/boston-scientific
Email: info@3blmedia.com

SOURCE: Boston Scientific

View source version on accesswire.com:
https://www.accesswire.com/741431/Representation-Matters-in-Clinical-Trials

FAQ

Why is diversity important in Boston Scientific's clinical trials?

Diversity in clinical trials is vital for ensuring that therapies effectively meet the needs of all patient demographics and to improve overall health outcomes.

What is Boston Scientific doing to improve representation in clinical trials?

Boston Scientific, in collaboration with Medtronic, is actively working to broaden patient demographics involved in their clinical trials.

Who spoke about the necessity of diversity in clinical trials?

Laura Mauri, MD, from Medtronic, discussed the social and clinical imperatives of diverse representation in clinical trials.

What are the potential impacts of improved diversity in clinical trials on patient outcomes?

By improving diversity in clinical trials, Boston Scientific aims to enhance the effectiveness of treatments and outcomes for a wider range of patients.